Cost ‐utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia

ConclusionIR can be considered a cost‐effective treatment compared to R, in the treatment of R/R CLL patients for the Spanish NHS.This article is protected by copyright. All rights reserved.
Source: European Journal of Haematology - Category: Hematology Authors: Tags: Original Article Source Type: research